世界のヒト免疫不全ウイルス（HIV）-1治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12357 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、84ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、ヒト免疫不全ウイルス（HIV）-1治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ヒト免疫不全ウイルス（HIV）-1治療の種類別市場規模（ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI）、侵入・融合阻害剤、プロテアーゼ阻害剤（PI）、インテグラーゼ阻害剤、共受容体拮抗薬）、用途別市場規模（病院、クリニック、実験室）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ヒト免疫不全ウイルス（HIV）-1治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AbbVie, Inc.(U.S.)、Merck & Co., Inc. (U.S.)、Bristol-Myers Squibb Company (U.S.)、Boehringer Ingelheim GmbH (Germany)、Genentech, Inc. (U.S.)、Cipla, Inc. (India) ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI）、侵入・融合阻害剤、プロテアーゼ阻害剤（PI）、インテグラーゼ阻害剤、共受容体拮抗薬 ・用途別分析2016年-2026年：病院、クリニック、実験室 ・ヒト免疫不全ウイルス（HIV）-1治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ヒト免疫不全ウイルス（HIV）-1治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ヒト免疫不全ウイルス（HIV）-1治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ヒト免疫不全ウイルス（HIV）-1治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ヒト免疫不全ウイルス（HIV）-1治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Human Immunodeficiency Virus (HIV)-1 Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Human Immunodeficiency Virus (HIV)-1 Therapeutics size is estimated to be USD 12600 million in 2026 from USD 12220 million in 2020, with a change XX% between 2020 and 2021. The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size is expected to grow at a CAGR of 0.8% for the next five years.

Market segmentation
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

Market segment by Application, can be divided into
Hospitals
Clinics
Labs

Market segment by players, this report covers
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Human Immunodeficiency Virus (HIV)-1 Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Human Immunodeficiency Virus (HIV)-1 Therapeutics, with revenue, gross margin and global market share of Human Immunodeficiency Virus (HIV)-1 Therapeutics from 2019 to 2021.
Chapter 3, the Human Immunodeficiency Virus (HIV)-1 Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Human Immunodeficiency Virus (HIV)-1 Therapeutics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Human Immunodeficiency Virus (HIV)-1 Therapeutics research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Human Immunodeficiency Virus (HIV)-1 Therapeutics
1.2 Classification of Human Immunodeficiency Virus (HIV)-1 Therapeutics by Type
1.2.1 Overview: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type in 2020
1.2.3 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
1.2.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.5 Entry and Fusion Inhibitors
1.2.6 Protease Inhibitors (PIs)
1.2.7 Integrase Inhibitors
1.2.8 Coreceptor Antagonists
1.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
1.3.1 Overview: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Labs
1.4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size & Forecast
1.5 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast by Region
1.5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers
1.6.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints
1.6.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Trends Analysis
2 Company Profiles
2.1 AbbVie, Inc.(U.S.)
2.1.1 AbbVie, Inc.(U.S.) Details
2.1.2 AbbVie, Inc.(U.S.) Major Business
2.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
2.1.4 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AbbVie, Inc.(U.S.) Recent Developments and Future Plans
2.2 Merck & Co., Inc. (U.S.)
2.2.1 Merck & Co., Inc. (U.S.) Details
2.2.2 Merck & Co., Inc. (U.S.) Major Business
2.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
2.2.4 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Merck & Co., Inc. (U.S.) Recent Developments and Future Plans
2.3 Bristol-Myers Squibb Company (U.S.)
2.3.1 Bristol-Myers Squibb Company (U.S.) Details
2.3.2 Bristol-Myers Squibb Company (U.S.) Major Business
2.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
2.3.4 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bristol-Myers Squibb Company (U.S.) Recent Developments and Future Plans
2.4 Boehringer Ingelheim GmbH (Germany)
2.4.1 Boehringer Ingelheim GmbH (Germany) Details
2.4.2 Boehringer Ingelheim GmbH (Germany) Major Business
2.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
2.4.4 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Boehringer Ingelheim GmbH (Germany) Recent Developments and Future Plans
2.5 Genentech, Inc. (U.S.)
2.5.1 Genentech, Inc. (U.S.) Details
2.5.2 Genentech, Inc. (U.S.) Major Business
2.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
2.5.4 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Genentech, Inc. (U.S.) Recent Developments and Future Plans
2.6 Cipla, Inc. (India)
2.6.1 Cipla, Inc. (India) Details
2.6.2 Cipla, Inc. (India) Major Business
2.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
2.6.4 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Cipla, Inc. (India) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players Market Share
3.2.2 Top 10 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2026)
6.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2026)
6.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country
6.3.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2026)
7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2026)
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country
7.3.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region
8.3.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Region (2016-2026)
8.3.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2026)
9.2 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2026)
9.3 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country
9.3.1 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country
10.3.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. AbbVie, Inc.(U.S.) Corporate Information, Head Office, and Major Competitors
Table 7. AbbVie, Inc.(U.S.) Major Business
Table 8. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
Table 9. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Merck & Co., Inc. (U.S.) Corporate Information, Head Office, and Major Competitors
Table 11. Merck & Co., Inc. (U.S.) Major Business
Table 12. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
Table 13. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bristol-Myers Squibb Company (U.S.) Corporate Information, Head Office, and Major Competitors
Table 15. Bristol-Myers Squibb Company (U.S.) Major Business
Table 16. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
Table 17. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Boehringer Ingelheim GmbH (Germany) Corporate Information, Head Office, and Major Competitors
Table 19. Boehringer Ingelheim GmbH (Germany) Major Business
Table 20. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
Table 21. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Genentech, Inc. (U.S.) Corporate Information, Head Office, and Major Competitors
Table 23. Genentech, Inc. (U.S.) Major Business
Table 24. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
Table 25. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Cipla, Inc. (India) Corporate Information, Head Office, and Major Competitors
Table 27. Cipla, Inc. (India) Major Business
Table 28. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
Table 29. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 31. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Players (2019-2021)
Table 32. Breakdown of Human Immunodeficiency Virus (HIV)-1 Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 33. Human Immunodeficiency Virus (HIV)-1 Therapeutics Players Head Office, Products and Services Provided
Table 34. Human Immunodeficiency Virus (HIV)-1 Therapeutics Mergers & Acquisitions in the Past Five Years
Table 35. Human Immunodeficiency Virus (HIV)-1 Therapeutics New Entrants and Expansion Plans
Table 36. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 37. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Type (2016-2021)
Table 38. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Forecast by Type (2021-2026)
Table 39. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2021)
Table 40. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Forecast by Application (2021-2026)
Table 41. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 42. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 43. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 44. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 45. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 46. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 47. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 48. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 49. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 50. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 51. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 52. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 53. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 54. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 55. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 56. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 57. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 58. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 59. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 60. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 61. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 62. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 63. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 64. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 65. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 66. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 67. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 68. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 69. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 70. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Picture
Figure 2. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type in 2020
Figure 3. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Figure 4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Figure 5. Entry and Fusion Inhibitors
Figure 6. Protease Inhibitors (PIs)
Figure 7. Integrase Inhibitors
Figure 8. Coreceptor Antagonists
Figure 9. Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Application in 2020
Figure 10. Hospitals Picture
Figure 11. Clinics Picture
Figure 12. Labs Picture
Figure 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Region (2016-2026)
Figure 16. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Region in 2020
Figure 17. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers
Figure 23. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints
Figure 24. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Trends
Figure 25. AbbVie, Inc.(U.S.) Recent Developments and Future Plans
Figure 26. Merck & Co., Inc. (U.S.) Recent Developments and Future Plans
Figure 27. Bristol-Myers Squibb Company (U.S.) Recent Developments and Future Plans
Figure 28. Boehringer Ingelheim GmbH (Germany) Recent Developments and Future Plans
Figure 29. Genentech, Inc. (U.S.) Recent Developments and Future Plans
Figure 30. Cipla, Inc. (India) Recent Developments and Future Plans
Figure 31. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Players in 2020
Figure 32. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 33. Global Top 3 Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share in 2020
Figure 34. Global Top 10 Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share in 2020
Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 36. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Type in 2020
Figure 37. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share Forecast by Type (2021-2026)
Figure 38. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Application in 2020
Figure 39. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share Forecast by Application (2021-2026)
Figure 40. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Type (2016-2026)
Figure 41. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Application (2016-2026)
Figure 42. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Country (2016-2026)
Figure 43. United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Type (2016-2026)
Figure 47. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Application (2016-2026)
Figure 48. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Country (2016-2026)
Figure 49. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Type (2016-2026)
Figure 55. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Region (2016-2026)
Figure 57. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Type (2016-2026)
Figure 64. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Application (2016-2026)
Figure 65. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Type (2016-2026)
Figure 69. Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Application (2016-2026)
Figure 70. Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Country (2016-2026)
Figure 71. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Methodology
Figure 75. Research Process and Data Source

---